Nazarin ya nuna cewa otezla 30 MG sau biyu a kullun cimma a hankali na kimantawa na duniya (SPGA-G) amsar Genetalia (SPGA-G) ta hanyar Genetalia (SPGA-G) ta hanyar Genetalia (SPGA-G) ta hanyar Genetalia (SPGA-G) ta hanyar Genetalia (SPGA-G) ta hanyar Genetalia (SPGA-G) ta hanyar Genetalia (a bayyane a matsayin SPGA-G na bayyane (0) ko kusan bayyane (1) tare da aƙalla raguwar maki 2 daga tushe) a mako na 16.

Bugu da kari, an kuma sadu da duk mahimman abubuwan ƙarshen na biyu tare da ma'ana da haɓakawa masu mahimmanci a cikin Matsalolin Matsakaicin Mahimmanci na Jiki (GPI-NRS) amsa (wanda aka ayyana azaman aƙalla raguwar maki 4 daga tushe a cikin ƙimar abu na GPI-NRS a cikin Alamomin Psoriasis na Genital Psoriasis. ga batutuwa masu ƙima na asali na ≥ 4); canjin yanayin yanayin jiki (BSA) ya canza daga asali; Ƙwararrun Ƙwararrun Ƙwararrun Rayuwa (DLQI) canza daga asali; da amsawar Kima ta Duniya na Likita (sPGA) (wanda aka ayyana azaman ƙimar sPGA na bayyananne (0) ko kusan bayyane (1) tare da aƙalla raguwar maki 2 daga tushe) a mako na 16 tare da Otezla tare da placebo.

Nau'in da adadin abubuwan da suka faru mara kyau da aka lura a cikin wannan gwaji sun yi daidai da sanannen bayanin martaba na Otezla. Abubuwan da aka fi sani da mummunan al'amuran da suka faru a cikin akalla 5% na marasa lafiya a cikin kowane rukunin jiyya sune gudawa, ciwon kai, tashin zuciya da nasopharyngitis.

Marasa lafiya da suka kammala kashi biyu na makafi na gwaji sun ci gaba ko sun canza zuwa Otezla a lokacin tsawan lokaci na binciken kuma za a bi da su ta hanyar mako 32. Binciken yana gudana kuma an shirya kammalawa a farkon rabin 2022.

Za a ƙaddamar da cikakkun sakamakon binciken na makonni 16 na makafi biyu don gabatarwa a taron likita mai zuwa.

A cikin Amurka, Otezla an amince da shi don kula da tsofaffi marasa lafiya tare da matsakaici zuwa matsananciyar plaque psoriasis waɗanda ke takarar phototherapy ko tsarin jiyya, manya marasa lafiya tare da cututtukan psoriatic amosanin gabbai da kuma ga manya masu fama da cututtukan baki masu alaƙa da Cutar Behcet. Tun lokacin amincewar FDA ta farko a cikin 2014, an wajabta Otezla ga marasa lafiya sama da 650,000 a duk duniya tare da psoriasis matsakaici-zuwa mai tsanani, cututtukan cututtukan psoriatic ko cutar Behcet.

ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:

Nazarin ya nuna cewa otezla 30 MG sau biyu a kullun cimma a hankali na kimantawa na duniya (SPGA-G) amsar Genetalia (SPGA-G) ta hanyar Genetalia (SPGA-G) ta hanyar Genetalia (SPGA-G) ta hanyar Genetalia (SPGA-G) ta hanyar Genetalia (SPGA-G) ta hanyar Genetalia (SPGA-G) ta hanyar Genetalia (a bayyane a matsayin SPGA-G na bayyane (0) ko kusan bayyane (1) tare da aƙalla raguwar maki 2 daga tushe) a mako na 16.
In addition, all secondary endpoints were also met with meaningful and significant improvements in Genital Psoriasis Itch Numerical Rating Scale (GPI-NRS) response (defined as at least a 4-point reduction from baseline in GPI-NRS item score within the Genital Psoriasis Symptoms for subjects with a baseline score of ≥ 4).
And static Physician’s Global Assessment (sPGA) response (defined as sPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline) at week 16 with Otezla versus placebo.